HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mozley, P. D. Articles by Alavi, A. Search for Related Content PubMed PubMed Citation Articles by Mozley, P. D. Articles by Alavi, A.

Biodistribution and Dosimetry of Iodine-123-IBF: A Potent Radioligand for Imaging the D2 Dopamine Receptor

Division of Nuclear Medicine and Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
Radiation Internal Dose Information Center, Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee

Correspondence: For correspondence or reprints contact: P. David Mozley, MD, 110 Donner Building, H.U.P., 3400 Spruce St., Philadelphia, PA 19104.

ABSTRACT

Iodine-123-labeled iodo-benzofuran (IBF) is a potent D2 dopamine receptor antagonist that has been developed as a potential SPECT imaging agent. This report documents its biodistribution and radiation dosimetry in seven healthy humans. Approximately 100 MBq of IBF were administered to each volunteer. Urine was collected to measure the fraction of the activity that was voided by the renal system. Conjugate images were serially acquired over 24 hr to determine the fraction of activity in the other organs. Standard image analysis techniques were used to measure the geometric mean count rates in the brain, GI tract, heart, liver, lungs and thyroid at each time point. Corrections for attenuation were made with ¹²³I transmission scans. Multicompartmental modeling was used to simulate and predict the bio-kinetic behavior of ¹²³I-IBF in the rest of the body. The absorbed doses for 24 organs were then estimated with the MIRD formalism. Rapid biological washout minimized the absorbed dose to most tissues. The excretory organs were exposed to the most radiation. The lower large intestine received about 0.13 mGy/MBq (0.48 rad/mCi), and the urinary bladder received 0.11 mGy/MBq. This low radiation burden will allow more than 370 MBq (10 mCi) to be administered to healthy research subjects during each study of the D2 receptor. Since high quality images of the brain can be obtained with half this amount, the findings suggest that ¹²³I-labeled IBF has a large margin of radiation safety in humans. Its stability in vivo and its high target-to-background contrast ratio in the human brain may make it a useful SPECT imaging agent.

This article has been cited by other articles:

				A. B. Newberg, N. A. Wintering, K. Plossl, J. Hochold, M. G. Stabin, M. Watson, D. Skovronsky, C. M. Clark, M.-P. Kung, and H. F. Kung Safety, Biodistribution, and Dosimetry of 123I-IMPY: A Novel Amyloid Plaque-Imaging Agent for the Diagnosis of Alzheimer's Disease J. Nucl. Med., May 1, 2006; 47(5): 748 - 754. [Abstract] [Full Text] [PDF]

				A. B. Newberg, K. Plossl, P. D. Mozley, J. B. Stubbs, N. Wintering, M. Udeshi, A. Alavi, T. Kauppinen, and H. F. Kung Biodistribution and Imaging with 123I-ADAM: A Serotonin Transporter Imaging Agent J. Nucl. Med., May 1, 2004; 45(5): 834 - 841. [Abstract] [Full Text] [PDF]